Cronos Group Swings to Q2 Profit on 58% Revenue Surge; New Anti-Dumping Probe Looms
CRON sits 54% above its 52-week low of $2.
Summary
Cronos Group reported a strong Q2 2026 with revenue up 58% and a swing to profitability, but a new Israeli anti-dumping investigation threatens its key growth market.
Key Events · Earnings and Guidance · CRON
-
Revenue Surges 58%
Q2 2026 net revenue reached $53.0 million, up from $33.5 million in Q2 2025, driven by higher cannabis flower sales in Israel and Germany and increased extract sales in Canada.
-
Swings to Profitability
Net income attributable to Cronos was $32.1 million ($0.09 per share) compared to a net loss of $39.7 million a year ago, helped by a $20.2 million foreign currency gain.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA improved to $13.1 million from $1.7 million in Q2 2025, reflecting higher gross profit and operating leverage.
-
Strong Balance Sheet & Buybacks
Cash and short-term investments totaled $797.0 million at quarter-end. The company repurchased $16.1 million in shares under a new $50 million program authorized in May 2026.
Analysis · CRON · Life Sciences
A sharp turnaround defined Cronos Group's Q2 2026, with net income reaching $35.7 million compared to a $38.5 million loss a year ago, propelled by a 58% jump in net revenue to $53.0 million. Gross margin expanded to 54% from 43%, and Adjusted EBITDA swung to $13.1 million from $1.7 million. The balance sheet remains fortress-like with $797 million in cash and short-term investments, and the company aggressively bought back $16.1 million in shares under a new $50 million program. Offsetting the strong quarter, Israel's Trade Levies Commissioner launched a fresh anti-dumping investigation on August 5, 2026 — a direct threat to Cronos's fast-growing Israeli medical cannabis business, which accounted for 28% of Q2 revenue. The investigation creates uncertainty around the company's most profitable growth engine.
At the time of this filing, CRON was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.00 to $3.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.